AU2003251826A1 - Mp21s as modifiers of the p21 pathway and methods of use - Google Patents

Mp21s as modifiers of the p21 pathway and methods of use

Info

Publication number
AU2003251826A1
AU2003251826A1 AU2003251826A AU2003251826A AU2003251826A1 AU 2003251826 A1 AU2003251826 A1 AU 2003251826A1 AU 2003251826 A AU2003251826 A AU 2003251826A AU 2003251826 A AU2003251826 A AU 2003251826A AU 2003251826 A1 AU2003251826 A1 AU 2003251826A1
Authority
AU
Australia
Prior art keywords
mp21s
modifiers
pathway
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003251826A
Other versions
AU2003251826A8 (en
Inventor
Joanne I. Adamkewicz
Craig D. Amundsen
Helen Francis-Lang
Lori Friedman
Bing Hai
Glenn R. Hammonds Jr.
Daniel M. Joo
Thomas Kidd
Kim Lickteig
Siobhan Roche
Haiguang Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of AU2003251826A1 publication Critical patent/AU2003251826A1/en
Publication of AU2003251826A8 publication Critical patent/AU2003251826A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AU2003251826A 2002-07-10 2003-07-09 Mp21s as modifiers of the p21 pathway and methods of use Abandoned AU2003251826A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US39479502P 2002-07-10 2002-07-10
US60/394,795 2002-07-10
US40173902P 2002-08-07 2002-08-07
US60/401,739 2002-08-07
US41101002P 2002-09-16 2002-09-16
US60/411,010 2002-09-16
US43715802P 2002-12-30 2002-12-30
US60/437,158 2002-12-30
PCT/US2003/021510 WO2004005486A2 (en) 2002-07-10 2003-07-09 Mp21s as modifiers of the p21 pathway and methods of use

Publications (2)

Publication Number Publication Date
AU2003251826A1 true AU2003251826A1 (en) 2004-01-23
AU2003251826A8 AU2003251826A8 (en) 2004-01-23

Family

ID=30119333

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003251826A Abandoned AU2003251826A1 (en) 2002-07-10 2003-07-09 Mp21s as modifiers of the p21 pathway and methods of use

Country Status (2)

Country Link
AU (1) AU2003251826A1 (en)
WO (1) WO2004005486A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008079877A2 (en) * 2006-12-22 2008-07-03 Xenon Pharmaceuticals Inc. Compositions and methods for the diagnosis and treatment of iron-related disorders
IT1406201B1 (en) * 2010-12-10 2014-02-14 Univ Degli Studi Trieste BIOMARCERS FOR DIAGNOSIS OF MULTIPLE SCLEROSIS

Also Published As

Publication number Publication date
WO2004005486A3 (en) 2006-04-27
AU2003251826A8 (en) 2004-01-23
WO2004005486A2 (en) 2004-01-15

Similar Documents

Publication Publication Date Title
AU2003224638A1 (en) PDPK1s AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
AU2003248879A1 (en) RABS AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
AU2002316631A1 (en) Ube2s as modifiers of the p21 pathway and methods of use
AU2003287802A1 (en) Palpometer and methods of use thereof
AU2003272390A1 (en) AMPDs AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
AU2003265263A1 (en) ADCY3S AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
AU2003251799A1 (en) Mchks as modifiers of the chk1 pathway and methods of use
AU2003258095A1 (en) MP21S AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
AU2003251826A1 (en) Mp21s as modifiers of the p21 pathway and methods of use
WO2005042707A9 (en) Taspasel 1 and methods of use
AU2003295881A1 (en) Lamps as modifiers of the p53 pathway and methods of use
AU2003274911A1 (en) Mrbs as modifiers of the rb pathway and methods of use
AU2003303094A1 (en) MAT2As AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
AU2003223208A1 (en) MP21s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
AU2003263993A1 (en) MP2153S AS MODIFIERS OF THE p21 OR p53 PATHWAY AND METHODS OF USE
AU2003294499A1 (en) Rhebs as modifiers of the rb pathway and methods of use
EP1578945A3 (en) Cct6s as modifiers of the rb pathway and methods of use
AU2003213693A1 (en) MCHKs AS MODIFIERS OF THE CHK PATHWAY AND METHODS OF USE
AU2003213665A1 (en) Lgals as modifiers of the chk pathway and methods of use
AU2003299990A1 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
AU2003217851A1 (en) MBCATs AS MODIFIERS OF THE BETA-CATENIN PATHWAY AND METHODS OF USE
AU2002354668A1 (en) Modifiers of the p21 pathway and methods of use
AU2003278811A1 (en) LDLRs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
AU2003248876A1 (en) MP53S AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
EP1540333A4 (en) Maxs as modifiers of the axin pathway and methods of use